Inovio, MedImmune partner under $45m DARPA Ebola contract
This article was originally published in Scrip
Executive Summary
Shares of Inovio Pharmaceuticals got a 8.6% boost on 8 April on the news the firm was named the prime contractor by the US Defense Advanced Research Projects Agency (DARPA) to lead a consortium of companies and academic researchers tapped to develop multiple treatment and prevention approaches against Ebola – a disease that has infected more than 25,500 people in the current outbreak in West Africa, killing over 10,500.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.